Lazertinib

CHEMBL4558324 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

554.6 g/mol

LogP

3.4

Phase

4

A third-generation EGFR tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations, including those that have developed resistance to earlier EGFR inhibitors. It crosses the blood-brain barrier, making it useful for patients with brain metastases.

الوزن الجزيئي

554,6000 g/mol

LogP

3,40

TPSA

110,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Non-Small Cell Lung Cancer

آلية العمل

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1

InChI

InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)

Molecular Formula

C30H34N8O3

HBD / HBA

2 / 9

الروابط القابلة للدوران

10

الذرات الثقيلة

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A third-generation EGFR tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations, including those that have developed resistance to earlier EGFR inhibitors. It crosses the blood-brain barrier, making it useful for patients with brain metastases.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Lazertinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4558324. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 121269225. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Lazertinib على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C30H34N8O3
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.